News from astellas pharma emea A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

24 Apr, 2017, 00:01 BST Use of Extended-Pulsed Regimen with DIFICLIR[TM] (fidaxomicin) is More Effective Than Standard vancomycin in Achieving Sustained Cure of Clostridium difficile Infection (CDI) and Preventing Recurrence[1]

CDI, a potentially fatal disease,[2] is three times as deadly as MRSA[3],[4] and is estimated to cost the EU €3 billion per annum[5] New data...


12 Dec, 2016, 07:00 GMT Astellas Announces Transfer of Qutenza™ to Grünenthal

Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, "Astellas"), today announced that Astellas Pharma Europe Ltd., ("Astellas Pharma...


28 Oct, 2016, 08:14 BST Astellas to Acquire Ganymed Pharmaceuticals

- Acquisition Would Expand Astellas' Oncology Pipeline with Antibody in Late-Stage - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko...


14 Oct, 2016, 08:00 BST World Anti-Doping Agency and Astellas Announce Global Initiative to Prevent Misuse and Abuse of Medicines for Doping in Sports

The World Anti-Doping Agency (President: Sir Craig Reedie, "WADA") and Astellas Pharma Inc. (TSE: 4503: President and CEO: Yoshihiko Hatanaka,...


11 Apr, 2016, 11:30 BST International Consensus Report Highlights Need for Improved Management of Clostridium difficile Infection (CDI) in Inflammatory Bowel Disease (IBD) Patients

In patients with IBD, CDI is a key risk factor for both morbidity and mortality, with disease interactions increasing the severity of patients'...


04 Mar, 2016, 08:00 GMT Astellas Pharma Europe Ltd. Announces New President of EMEA Operations

Astellas Pharma Europe Ltd., a subsidiary of Astellas Pharma Inc. (TSE:4503), is pleased to announce that Mr Yukio Matsui has been appointed as...


18 Sep, 2015, 09:00 BST Astellas Granted Label Extension for QUTENZA[TM] (capsaicin 8% patch) to Include Treatment of Diabetic Patients With Peripheral Neuropathic Pain (PNP)

Astellas Pharma Europe Ltd. today announced the European Commission has granted approval for a label extension for QUTENZA[TM] (capsaicin 8% patch)...


16 Sep, 2015, 11:28 BST Astellas Pharma EMEA appoints Eugene Van Rensburg as Chief Financial Officer

Astellas Pharma EMEA, the regional headquarters of Astellas Pharma Inc. for Europe, the Middle East and Africa, has appointed Eugene Van Rensburg to...


28 Aug, 2015, 09:00 BST Over 550 Women's Lives Transformed to-Date With Action on Fistula

Groundbreaking campaign ends one woman's 51 year wait for surgical treatment Females aged from seven to 90 years old treated for devastating...


19 May, 2015, 16:10 BST DIFICLIR[TM]▼ (Fidaxomicin) Significantly Reduces Recurrence and All-Cause Mortality When Used First-Line in all Patients With Clostridium Difficile Infection (CDI)

In the UK, there were 16,947 reported cases of CDI between April 2013 and March 2014[1],[2],[3],[4] and in 2012 CDI contributed to nearly 1,900...


19 May, 2015, 15:03 BST DIFICLIR[TM] (Fidaxomicin) Significantly Reduces Recurrence and All-Cause Mortality When Used First-Line in All Patients Diagnosed With Clostridium Difficile Infection (CDI)

In Europe the incidence and severity of CDI is increasing,[1],[2],[3],[4] with nearly 125,000 cases a year,[5] posing a major threat to healthcare...


27 Jan, 2015, 17:14 GMT m-Health Pioneer Professor Lionel Tarassenko Joins Panel at The Astellas Innovation Debate™

i-Genes: What the DNA and Data Revolutions mean for our Health Chaired by Jonathan Dimbleby Keynote Speaker: George Freeman, MP, Minister for Life...


27 Jan, 2015, 16:37 GMT Professor Rolf Stahel, President of ESMO Joins Panel at The Astellas Innovation Debate[TM]

i-Genes: What the DNA and Data Revolutions mean for our Health Chaired by Jonathan Dimbleby Keynote Speaker: George Freeman, MP, Minister for Life...


26 Jan, 2015, 18:19 GMT Technology Will Enable Healthcare to Focus on Wellness Rather Than Illness, US Bio-entrepreneur Dr Leroy Hood to Tell The Astellas Innovation Debate™

i-Genes: What the DNA and Data Revolutions mean for our Health Chaired by Jonathan Dimbleby Keynote Speaker: George Freeman, MP, Minister for Life...


19 Jan, 2015, 17:00 GMT George Freeman MP, Minister for Life Sciences to Give Keynote Address at The Astellas Innovation Debate(TM)

i-Genes: What the DNA and Data Revolutions mean for our Health Chaired by Jonathan Dimbleby Royal Institution of Great Britain, Thursday 29th January ...


19 Jan, 2015, 16:25 GMT Baroness Helena Kennedy, QC, Joins Panel at The Astellas Innovation Debate(TM) 2015

i-Genes: What the DNA and Data Revolutions mean for our Health Chaired by Jonathan Dimbleby Keynote Speaker: George Freeman, MP, Minister for Life...


02 Dec, 2014, 10:30 GMT Experts Attend European Parliament to Call for Urgent Action to Improve Clostridium Difficile Infection Management in Europe

Event coincides with the publication in The Lancet Infectious Diseases of EUCLID - the largest epidemiology study on Clostridium difficile...


26 Nov, 2014, 06:00 GMT UK's Most Innovative School Students Awarded for Mobile Health App Ideas to Boost Healthy Living

TV presenter Rachel Riley crowns winners of the Astellas Innovation Challenge™, a health app-design competition to inspire school students to take up ...


26 Nov, 2014, 00:01 GMT DIFICLIR™ (fidaxomicin) proven to be both clinically and cost-effective compared to standard of care in real-world patients with Clostridium difficile infection

Recurrence has been identified by The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) as the most important problem in the ...


07 Sep, 2014, 08:00 BST DIFICLIR[TM] (fidaxomicin) is More Cost Effective Than Current Standard of Care in Cancer Patients, a Vulnerable Population at High Risk of Clostridium Difficile Infection

Clostridium difficile infection (CDI) is estimated to cost the EU €3 billion per annum and is expected to almost double over the next four decades[1] ...


05 Sep, 2014, 13:47 BST Enzalutamide Significantly Reduces Morbidities Associated With Bone Metastases in Men With Metastatic Castration-Resistant Prostate Cancer

- New Results From the AFFIRM Trial Published in Lancet Oncology Enzalutamide (XTANDI™) reduces the risk of skeletal-related events compared with...


08 Aug, 2014, 09:40 BST Astellas Pharma EMEA anuncia sus nuevos nombramientos senior

Astellas Pharma EMEA, la sede regional de Astellas Pharma Inc. para Europa, Oriente Medio y África, ha nombrado a Simon Dew para que ocupe el cargo...


07 Aug, 2014, 12:24 BST Astellas Pharma EMEA Announces New Senior Appointments

Astellas Pharma EMEA, the regional headquarters of Astellas Pharma Inc. for Europe, the Middle East and Africa, has appointed Simon Dew to the...